Skip to main content
Clinical Trials/NCT05437003
NCT05437003
Completed
Not Applicable

A Cross-Sectional Study to Evaluate the Correlation Between Oculometric Measures and MDS-UPDRS in Patients With Idiopathic Parkinson's Disease (PD) and Evaluation of Oculometric Measures in Healthy Participants

NeuraLight1 site in 1 country465 target enrollmentAugust 20, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Idiopathic Parkinson Disease
Sponsor
NeuraLight
Enrollment
465
Locations
1
Primary Endpoint
Correlation between MDS-UPDRS score and its parts with NeuraLight oculometric measurements
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

This is a prospective study in a cohort of about 500 patients with Idiopathic Parkinson's disease, examined routinely in the neurological outpatient clinic.

This study aims to evaluate the correlation between oculometric measures and clinical endpoints. Subjects will be evaluated following a physician examination.The evaluations will include MDS-UPDRS examination, as well as an oculometric evaluation for eye movements. In addition, 500 healthy subjects will be evaluated.

Detailed Description

This is a prospective study in a cohort of patients with idiopathic PD who are visiting the Parkinson's outpatient clinic. The aim of the study is to evaluate the correlation between oculometric measures and MDS-UPDRS score in subjects who meet the inclusion criteria and who provide a signed Informed Consent. This study is designed to evaluate the correlation between oculometric measures and the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Subjects will be evaluated at their visit to the clinic. The evaluations will include an MDS-UPDRS examination by a certified neurologist and other tests. In addition, all patients will undergo a NeuraLight session for oculometric evaluation along with eye-tracking recordings. All assessments will be performed during a clinic visit unless authorized to be conducted remotely. In addition, 500 healthy subjects will be evaluated, undergoing a NeuraLight session for oculometric evaluation along with eye-tracking recordings.

Registry
clinicaltrials.gov
Start Date
August 20, 2022
End Date
February 15, 2024
Last Updated
2 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
NeuraLight
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Men and women with idiopathic PD (Hoehn \& Yahr scale 1-5)
  • Age between 18 and 85 years old
  • Normal or corrected vision
  • Ability to follow instructions
  • Willing and able to sign an informed consent form

Exclusion Criteria

  • Inability to sit for 20 minutes on a chair in a calm manner
  • Personal or 1st degree relative history of epilepsy
  • Additional neurological diseases
  • Drug or alcohol abuse
  • Healthy subjects:
  • Inclusion Criteria:
  • Age between 18 and 85 years old
  • Normal or corrected vision
  • Ability to follow instructions
  • Willing and able to sign an informed consent form

Outcomes

Primary Outcomes

Correlation between MDS-UPDRS score and its parts with NeuraLight oculometric measurements

Time Frame: 12 months

The correlation between MDS-UPDRS score and its parts with NeuraLight oculometric measurements (R-Square\>0.5, p\<0.05) according to the Movement Disorder Society-Sponsored Unified Parkinson's Disease Rating Scale (MDS-UPDRS) at every visit

Comparison of NeuraLight extracted oculometric measures with a validated eye-tracking system

Time Frame: 12 months

Relative root mean square error (RMSE) of NeuraLight's extracted oculometric measures compared with retrieved measurements from a validated eye tracking system \<0.1

Feasibility of using NeuraLight system to capture oculometric measures in a cohort of PD patients and healthy subjects

Time Frame: 12 months

Capturing \>50 different oculometric measures in \>95% of a cohort of about 1000 patients

Secondary Outcomes

  • Using the retrieved data of collected NeuraLight oculometric measures for calibration of prediction models of MDS-UPDRS clinical endpoint(12 months)

Study Sites (1)

Loading locations...

Similar Trials